Publication: Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure
Issued Date
2008-01-01
Resource Type
ISSN
15455017
15455009
15455009
Other identifier(s)
2-s2.0-36849024880
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pediatric Blood and Cancer. Vol.50, No.1 (2008), 169-172
Suggested Citation
Nongnuch Sirachainan, Anannit Visudtibhan, Lojana Tuntiyatorn, Samart Pakakasama, Ampaiwan Chuansumrit, Suradej Hongeng Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure. Pediatric Blood and Cancer. Vol.50, No.1 (2008), 169-172. doi:10.1002/pbc.20848 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/19795
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure
Other Contributor(s)
Abstract
A 3-year-old male, diagnosed with stage 4 neuroblastoma, developed recurrent leptomeningeal metastasis after multi-modality treatment including multi-agent chemotherapy, surgery, high dose chemotherapy plus stem ceil rescue, cis-retinoic acid and intravenous (IV) topotecan. He then received intraommaya (IO) topotecan three times weekly (maximum dose; 0.4 mg). A complete response was achieved by a resolution of malignant cells in cerebrospinal fluid and resolution leptomeningeal enhancement by brain MRI. Treatment toxicities included low-grade fever and minimal headache. The duration of treatment response from IO topotecan was 18 weeks. The survival time from CNS recurrence in this patient was 13 months. We suggest IO topotecan be considered for neoplastic meningitis of tumors with known sensitivity to topotecan. © 2006 Wiley-Liss, Inc.